Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 9;57(4):912-925.e4.
doi: 10.1016/j.immuni.2024.02.017. Epub 2024 Mar 14.

Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants

Affiliations
Free article

Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants

Timothy S Johnston et al. Immunity. .
Free article

Abstract

The spike glycoprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to accumulate substitutions, leading to breakthrough infections of vaccinated individuals. It remains unclear if exposures to antigenically distant SARS-CoV-2 variants can overcome memory B cell biases established by initial SARS-CoV-2 encounters. We determined the specificity and functionality of antibody and B cell responses following exposure to BA.5 and XBB variants in individuals who received ancestral SARS-CoV-2 mRNA vaccines. BA.5 exposures elicited antibody responses that targeted epitopes conserved between the BA.5 and ancestral spike. XBB exposures also elicited antibody responses that primarily targeted epitopes conserved between the XBB.1.5 and ancestral spike. However, unlike BA.5, a single XBB exposure elicited low frequencies of XBB.1.5-specific antibodies and B cells in some individuals. Pre-existing cross-reactive B cells and antibodies were correlated with stronger overall responses to XBB but weaker XBB-specific responses, suggesting that baseline immunity influences the activation of variant-specific SARS-CoV-2 responses.

Keywords: B cells; Omicron BA.5; SARS-CoV-2; XBB.1.5; antibodies; immune evasion; immune imprinting; mRNA vaccines; original antigenic sin; viral evolution.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests E.J.W. is a member of the Parker Institute for Cancer Immunotherapy. E.J.W. is an advisor for Arsenal Biosciences, Coherus, Danger Bio, IpiNovyx, Janssen, New Limit, Marengo, Pluto Immunotherapeutics Related Sciences, Santa Ana Bio, and Synthekine. E.J.W. is a founder of and holds stock in Coherus, Danger Bio, and Arsenal Biosciences. S.E.H. reports receiving consulting fees from Sanofi Vaccines, Lumen, Novavax, and Merck. S.E.H. is a co-inventor on patents that describe the use of nucleoside-modified mRNA as a vaccine platform.

Update of

Publication types

Supplementary concepts